Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1986-3-5
|
| pubmed:abstractText |
Nicardipine, a new calcium antagonist, was tested in a 14-week double-blind trial including 15 outpatients with uncomplicated essential hypertension. They were randomly assigned to nicardipine (20-30 mg three times daily) or placebo as first-step treatment. When necessary but always after a minimum of 4 weeks, pindolol (15 mg/day) was combined with nicardipine or placebo. At the end of step 1 (85 +/- 6 days with nicardipine vs. 58 +/- 6 days with placebo, p less than 0.01), nicardipine induced larger drops in supine systolic and diastolic blood pressure (SBP and DBP) than the placebo (21 +/- 2.5 vs 1.4 +/- 3 mm Hg, p less than 0.001, and 13 +/- 2 vs. 3.5 +/- 1.5 mm Hg, p less than 0.001, respectively). In the nicardipine group (n = 57), 53% of patients had controlled blood pressure (SBP less than 160 mm Hg and DBP less than 95 mm Hg) versus 17% in the placebo group (n = 47), p less than 0.001. There was no significant correlation between the decrease in blood pressure and the age of patients. The most common side effects in the nicardipine group were flushes (12%), headache (8%), ankle edema (5%), and asthenia (4%). When blood pressure was not brought under control and pindolol was prescribed as the second-step treatment, the nicardipine group (n = 52) displayed larger drops in SBP and DBP than the placebo group (n = 40) (27 +/- 5 vs. 15 +/- 3 mm Hg, p less than 0.01, and 18 +/- 1 vs. 9 +/- 2 mm Hg, p less than 0.001, respectively). These results show that a calcium antagonist is useful for first-step treatment of hypertension.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0160-2446
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1149-53
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2418302-Adult,
pubmed-meshheading:2418302-Aged,
pubmed-meshheading:2418302-Blood Pressure,
pubmed-meshheading:2418302-Calcium Channel Blockers,
pubmed-meshheading:2418302-Clinical Trials as Topic,
pubmed-meshheading:2418302-Double-Blind Method,
pubmed-meshheading:2418302-Drug Therapy, Combination,
pubmed-meshheading:2418302-Female,
pubmed-meshheading:2418302-Heart Rate,
pubmed-meshheading:2418302-Humans,
pubmed-meshheading:2418302-Hypertension,
pubmed-meshheading:2418302-Male,
pubmed-meshheading:2418302-Middle Aged,
pubmed-meshheading:2418302-Nicardipine,
pubmed-meshheading:2418302-Nifedipine,
pubmed-meshheading:2418302-Pindolol,
pubmed-meshheading:2418302-Random Allocation,
pubmed-meshheading:2418302-Time Factors
|
| pubmed:articleTitle |
First-step treatment of mild to moderate uncomplicated essential hypertension by a new calcium antagonist: nicardipine.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|